文献速递妇科

铂类治疗缓解后卵巢癌患者接种叶酸受体α肽疫苗:一项随机多中心临床试验

Vaccination with folate receptor-alpha peptides in patients with ovarian cancer following response to platinum-based therapy: A randomized, multicenter clinical trial.
PubMed 文献 · Gynecol Oncol · 2024-07-27

这项随机双盲多中心II期研究在120例至少4周期一线铂类治疗后未进展的卵巢癌患者中,比较TPIV200(多表位FRα肽疫苗混合GM-CSF)与单用GM-CSF的安全性和疗效。中位随访15.2个月时,两组疾病进展比例分别为55%和59%,中位无进展生存期无显著差异,未出现≥3级药物相关不良事件。

要点

  • TPIV200疫苗耐受性良好,未发生≥3级药物相关不良事件。
  • TPIV200+GM-CSF组中位PFS 10.9个月,单用GM-CSF组11.1个月,无显著差异。
  • 作者认为需进一步研究多表位FRα疫苗的潜在协同作用。

核心结论

  • TPIV200耐受性良好,但未改善无进展生存期。
  • 作者认为需进一步研究靶向FRα的多表位疫苗的潜在协同作用。

研究设计与样本

  • 随机、双盲、多中心II期研究,纳入120例至少接受4周期一线铂类治疗后未进展的卵巢癌女性。
  • 患者每4周皮内接种一次,最多6次,随后为6次每12周间隔的加强接种。
  • 主要终点包括安全性、耐受性和无进展生存期。

主要发现

  • 中位随访15.2个月(范围1.2-28.4个月)时,119例意向治疗患者中68例疾病进展(TPIV200+GM-CSF组55%,单用GM-CSF组59%)。
  • 中位PFS为11.1个月(95% CI 8.3-16.6个月),两组无显著差异(TPIV200+GM-CSF组10.9个月 vs 单用GM-CSF组11.1个月,HR 0.85;90% CI上限1.17)。
  • 无患者发生≥3级药物相关不良事件。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 作者认为需进一步研究以揭示靶向FRα的多表位疫苗的潜在协同作用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Folate receptor alpha (FRα) is overexpressed on >90% of high-grade epithelial ovarian cancers (EOC). Targeting FRα with antibody-drug conjugates has proven utility in the platinum-resistant setting. It is also a potential therapeutic target for immuno-oncologic agents, such as peptide vaccines that work primarily via adaptive and humoral immunity. We tested the hypothesis that FRα peptide immunization could improve outcomes in patients with EOC following response to platinum-based therapy. METHODS: We conducted a randomized, double-blind, multicenter, phase II study to evaluate the safety and efficacy of TPIV200 (a multi-epitope FRα peptide vaccine admixed with GM-CSF) versus GM-CSF alone in 120 women who did not have disease progression after at least 4 cycles of first-line platinum-based therapy. Patients were vaccinated intradermally once every 4 weeks up to 6 times, followed by a boosting period of 6 vaccinations at 12-week intervals. Primary endpoints included safety, tolerability, and progression free survival (PFS). RESULTS: At study termination with a median follow-up of 15.2 months (range 1.2-28.4 months), 68 of 119 intention-to-treat patients had disease progression (55% in TPIV200 + GM-CSF arm and 59% in GM-CSF alone arm). The median PFS was 11.1 months (95% CI 8.3-16.6 months) with no significant difference between the treatment groups (10.9 months with TPIV200 + GM-CSF versus 11.1 months with GM-CSF, HR, 0.85; upper 90% CI 1.17]. No patient experienced a ≥ grade 3 drug-related adverse event. CONCLUSION: TPIV200 was well tolerated but was not associated with improved PFS. Additional studies are required to uncover potential synergies using multiepitope vaccines targeting FRα. Trial Registration NLM/NCBI Registry, NCT02978222, https://clinicaltrials.gov/search?term=NCT02978222.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Gupta A, O'Cearbhaill RE, Block MS, et al. Vaccination with folate receptor-alpha peptides in patients with ovarian cancer following response to platinum-based therapy: A randomized, multicenter clinical trial. Gynecol Oncol. 2024. PMID: 39068739. doi:10.1016/j.ygyno.2024.07.675

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。